Incyte reports data from Phase IIb vitiligo therapy trial

Incyte has reported data from a Phase IIb clinical trial of povorcitinib (INCB54707) in extensive nonsegmental vitiligo adult patients.

The placebo-controlled, randomised, dose ranging, double-blind Phase IIb trial has been designed for assessing povorcitinib’s safety and efficacy in these patients.